Research & development increased 46.2%
Research & development changed +46.2% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +46.2% from the comparable as-filed period.
Operating cash flow changed +370.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
SBC / revenue changed -555 basis points from the comparable as-filed period.
Receivables / revenue changed -6076 basis points from the comparable as-filed period.
Operating cash-flow margin changed +4709 basis points from the comparable as-filed period.
Operating income changed -355.1% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
R&D / revenue changed -205 basis points from the comparable as-filed period.
Current ratio changed -12.8% from the comparable as-filed period.
Stock-based compensation changed +13.8% from the comparable as-filed period.
Working capital / assets changed -103 basis points from the comparable as-filed period.
Free-cash-flow margin changed -5 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.